Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Search

Page Path

HOME
Search

Original Article

Vimentin as a potential therapeutic target in sorafenib resistant HepG2, a HCC model cell line

Ankita Makol, Harpreet Kaur, Sakshi Sharma, Shruthi Kanthaje, Ramanpreet Kaur, Anuradha Chakraborti

Clin Mol Hepatol. 2020;26(1):45-53. Published online September 30, 2019

DOI: https://doi.org/10.3350/cmh.2019.0031

View: 7608 Download: 250 Web of Science: 17 Crossref: 14

1 |

Clinical and
Molecular
Hepatology

Print ISSN: 2287-2728
Online ISSN: 2287-285X

Impact Factor

8.9
First decision

09 Days

Publication after acceptance

04 Days

*Last 12 months

MOST VIEWED (Last 6 months)

Viewed By 5257	Prognostic value of ultra-low-pass whole-genome sequencing of circulating tumor DNA in hepatocellular carcinoma under systemic treatment
Viewed By 5200	MAFLD: How is it different from NAFLD?
Viewed By 5108	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 3832	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Viewed By 3764	Global incidence and prevalence of nonalcoholic fatty liver disease

+more

MOST CITED (2022-2024)

Cited By 114	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 103	2022 KLCA-NCC Korea practice guidelines for the management of hepatocellular carcinoma
Cited By 76	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 65	Forecasted 2040 global prevalence of nonalcoholic fatty liver disease using hierarchical bayesian approach
Cited By 52	MAFLD: How is it different from NAFLD?

+more

Editorial Office
The Korean Association for the Study of the Liver
Room A1210, 53 Mapo-daero(MapoTrapalace, Dowha-dong), Mapo-gu, Seoul, 04158, Korea
TEL: +82-2-703-0051 FAX: +82-2-703-0071 E-mail: kasl@kams.or.kr

COUNTER

TODAY : 771

TOTAL : 1789514